SUNPHARMA — Sun Pharmaceutical Industries Share Price
0.000.00%
Last trade - 00:00- IN₹4.01tn
- IN₹3.77tn
- IN₹525.78bn
- 94
- 16
- 77
- 71
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 31.01 | ||
| PEG Ratio (f) | 3.42 | ||
| EPS Growth (f) | 9.98% | ||
| Dividend Yield (f) | 0.97% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.55 | ||
| Price to Tang. Book | 7.39 | ||
| Price to Free Cashflow | 33.59 | ||
| Price to Sales | 7.63 | ||
| EV to EBITDA | 26.04 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 16.11% | ||
| Return on Equity | 16.09% | ||
| Operating Margin | 22.64% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 334,981.4 | 386,544.9 | 438,856.8 | 484,968.5 | 525,784.4 | 572,138.64 | 626,763.09 | 9.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +61.43 | +4.98 | +28.43 | +15.91 | +14.83 | +8.16 | +14.28 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
Directors
- Israel Makov NEC (82)
- C. S. Muralidharan CFO
- Uday Baldota CEX (51)
- Abhay Gandhi CEX
- Kirti Ganorkar CEX (54)
- Anilkumar Jain CEX
- Jila Breeze EVP
- Pradeep Sanghvi EVP
- Aalok Shanghvi EVP
- Davinder Singh EVP
- Sapna Purohit SVP
- Azadar Khan SVP
- Sreenivas Rao SVP
- Anoop Deshpande CCO
- Dilip Shanghvi MDR (65)
- Sailesh Desai EDR (65)
- Subramanian Kalyanasundaram EDR
- Kalyanasundaram Subramanian EDR (67)
- Hellen De Kloet OTH
- Sudhir Valia NED (64)
- Rama Bijapurkar IND
- Pawan Goenka IND (66)
- Gautam Doshi NID (68)
- Rekha Sethi NID
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- March 1st, 1993
- Public Since
- January 1st, 1994
- No. of Shareholders
- 729,019
- No. of Employees
- 43,000
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 2,399,334,970
- Address
- Sun House, CTS No. 201 B/1,, Western Exp, MUMBAI, 400063
- Web
- https://sunpharma.com/
- Phone
- +91 2243244324
- Contact
- Abhishek Sharma
- Auditors
- S R B C & CO LLP
Upcoming Events for SUNPHARMA
Sun Pharmaceutical Industries Ltd Annual Shareholders Meeting
Q2 2026 Sun Pharmaceutical Industries Ltd Earnings Release
Similar to SUNPHARMA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Sun Pharmaceutical Industries share price?
As of Today at 23:30 UTC, shares in Sun Pharmaceutical Industries are trading at IN₹1,672.00. This share price information is delayed by 15 minutes.
How has the Sun Pharmaceutical Industries share price performed this year?
Shares in Sun Pharmaceutical Industries last closed at IN₹1,672.00 and the price had moved by +5.71% over the past 365 days. In terms of relative price strength the Sun Pharmaceutical Industries share price has outperformed the S&P BSE 100 Index by +3.59% over the past year.
What are the analyst and broker recommendations for Sun Pharmaceutical Industries?
The overall consensus recommendation for Sun Pharmaceutical Industries is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sun Pharmaceutical Industries dividend yield?
The Sun Pharmaceutical Industries dividend yield is 0.96% based on the trailing twelve month period.
Does Sun Pharmaceutical Industries pay a dividend?
Last year, Sun Pharmaceutical Industries paid a total dividend of IN₹16.00, and it currently has a trailing dividend yield of 0.96%.Looking ahead, the next dividend pay date is 2025-08-08.
When does Sun Pharmaceutical Industries next pay dividends?
We do not have data on when Sun Pharmaceutical Industries is to next pay dividends. The historic dividend yield on Sun Pharmaceutical Industries shares is currently 0.96%.
How do I buy Sun Pharmaceutical Industries shares?
To buy shares in Sun Pharmaceutical Industries you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sun Pharmaceutical Industries?
As of the previous close price of IN₹1,672.00, shares in Sun Pharmaceutical Industries had a market capitalisation of IN₹4.01tn.
Where are Sun Pharmaceutical Industries shares listed?
Here are the trading details for Sun Pharmaceutical Industries:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SUNPHARMA
What kind of share is Sun Pharmaceutical Industries?
Based on an overall assessment of its quality, value and momentum Sun Pharmaceutical Industries is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sun Pharmaceutical Industries share price forecast for 2025?
The analyst consensus target price for shares in Sun Pharmaceutical Industries is IN₹1,973.65. That is 18.04% above the last closing price of IN₹1,672.00.
Analysts covering Sun Pharmaceutical Industries currently have a consensus Earnings Per Share (EPS) forecast of IN₹51.83 for the next financial year.
Find out moreWhat is the trend in the Sun Pharmaceutical Industries share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sun Pharmaceutical Industries. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -14.22%.
As of the last closing price of IN₹1,672.00, shares in Sun Pharmaceutical Industries were trading -5.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sun Pharmaceutical Industries PE Ratio?
The Sun Pharmaceutical Industries PE ratio based on its reported earnings over the past 12 months is 31.01. The shares last closed at IN₹1,672.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries' management team is headed by:
- Israel Makov - NEC
- C. S. Muralidharan - CFO
- Uday Baldota - CEX
- Abhay Gandhi - CEX
- Kirti Ganorkar - CEX
- Anilkumar Jain - CEX
- Jila Breeze - EVP
- Pradeep Sanghvi - EVP
- Aalok Shanghvi - EVP
- Davinder Singh - EVP
- Sapna Purohit - SVP
- Azadar Khan - SVP
- Sreenivas Rao - SVP
- Anoop Deshpande - CCO
- Dilip Shanghvi - MDR
- Sailesh Desai - EDR
- Subramanian Kalyanasundaram - EDR
- Kalyanasundaram Subramanian - EDR
- Hellen De Kloet - OTH
- Sudhir Valia - NED
- Rama Bijapurkar - IND
- Pawan Goenka - IND
- Gautam Doshi - NID
- Rekha Sethi - NID